Literature DB >> 16611058

HAART-persistent HIV-1 latent reservoirs: their origin, mechanisms of stability and potential strategies for eradication.

Joseph Kulkosky1, Stacie Bray.   

Abstract

HIV-1 infection persists despite long-term administration of highly active antiretroviral therapy (HAART). The mechanism of this persistence appears to result primarily from viral infection of CD4+ T-lymphocytes that have the ability to duplicate and revert into a quiescent state. These infected resting cells are long-lived and evade immune surveillance or clearance. The inability to eradicate this class of cells, bearing the viral DNA, suggests life-long persistence of virus in HIV-1-infected individuals, even if HAART were administered for decades. This review discusses the origins and mechanisms accounting for stability of these latent HIV-1 cellular reservoirs. It further provides an overview of recent clinical trials aimed at their eradication. There have been a limited number of immune activation (IAT) trials directed at HAART-persistent, viral reservoir eradication. These trials have not resulted in purging of these highly stable viral reservoirs though results from such efforts suggest partial effects. The properties of novel compounds that might be included into IAT eradication protocols are continuing to be evaluated and their potential for inclusion into future IAT trials will be discussed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16611058     DOI: 10.2174/157016206776055084

Source DB:  PubMed          Journal:  Curr HIV Res        ISSN: 1570-162X            Impact factor:   1.581


  19 in total

1.  Supernatants from oral epithelial cells and gingival fibroblasts modulate human immunodeficiency virus type 1 promoter activation induced by periodontopathogens in monocytes/macrophages.

Authors:  O A González; J L Ebersole; C B Huang
Journal:  Mol Oral Microbiol       Date:  2010-04       Impact factor: 3.563

2.  Highly potent, synthetically accessible prostratin analogs induce latent HIV expression in vitro and ex vivo.

Authors:  Elizabeth J Beans; Dennis Fournogerakis; Carolyn Gauntlett; Lars V Heumann; Rainer Kramer; Matthew D Marsden; Danielle Murray; Tae-Wook Chun; Jerome A Zack; Paul A Wender
Journal:  Proc Natl Acad Sci U S A       Date:  2013-06-28       Impact factor: 11.205

3.  Clinical implications of new findings in HIV basic research.

Authors:  Manish Sagar
Journal:  HIV Ther       Date:  2009-07-01

4.  Response of a simian immunodeficiency virus (SIVmac251) to raltegravir: a basis for a new treatment for simian AIDS and an animal model for studying lentiviral persistence during antiretroviral therapy.

Authors:  Mark G Lewis; Sandro Norelli; Matt Collins; Maria Letizia Barreca; Nunzio Iraci; Barbara Chirullo; Jake Yalley-Ogunro; Jack Greenhouse; Fausto Titti; Enrico Garaci; Andrea Savarino
Journal:  Retrovirology       Date:  2010-03-16       Impact factor: 4.602

5.  Improved oral bioavailability and brain transport of Saquinavir upon administration in novel nanoemulsion formulations.

Authors:  Tushar K Vyas; Aliasgar Shahiwala; Mansoor M Amiji
Journal:  Int J Pharm       Date:  2007-06-19       Impact factor: 5.875

Review 6.  Lessons learned from HIV vaccine clinical efficacy trials.

Authors:  Tracey A Day; James G Kublin
Journal:  Curr HIV Res       Date:  2013-09       Impact factor: 1.581

7.  Soluble PD-1 rescues the proliferative response of simian immunodeficiency virus-specific CD4 and CD8 T cells during chronic infection.

Authors:  Nattawat Onlamoon; Kenneth Rogers; Ann E Mayne; Kovit Pattanapanyasat; Kazuyasu Mori; Francois Villinger; Aftab A Ansari
Journal:  Immunology       Date:  2008-02-05       Impact factor: 7.397

8.  Persistent hijacking of brain proteasomes in HIV-associated dementia.

Authors:  Trung P Nguyen; Vicki M Soukup; Benjamin B Gelman
Journal:  Am J Pathol       Date:  2009-12-24       Impact factor: 4.307

9.  Antiretroviral drugs: critical issues and recent advances.

Authors:  Mira Desai; Geetha Iyer; R K Dikshit
Journal:  Indian J Pharmacol       Date:  2012-05       Impact factor: 1.200

10.  In vivo effects of antiviral protein kinase C modulators on zebrafish development and survival.

Authors:  Richard V Davis; Lisa N McKernan; Jennifer Rhodes; Joseph Kulkosky
Journal:  ISRN Toxicol       Date:  2011-12-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.